MEDCAP AB SK-40
Research MEDCAP AB SK-40 (61MA) on Bullrun: valuation model: 39.0% overvalued, market cap EUR 695.02M, P/E 34.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker61MA
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencyEUR
- Valuation signal39.0% overvalued
- Market capEUR 695.02M
- P/E34.1
- Financial periodFY2024
- RevenueSEK 1.81B
- Revenue growth13.8%
- Net incomeSEK 209.20M
- Free cash flowSEK 318.30M
Valuation Snapshot
Bullrun's latest valuation model marks MEDCAP AB SK-40 as 39.0% overvalued; latest market cap is EUR 695.02M; P/E is 34.1.
About MEDCAP AB SK-40
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products;
Frequently asked questions
Is MEDCAP AB SK-40 overvalued or undervalued?
Bullrun's valuation model currently marks MEDCAP AB SK-40 as 39.0% overvalued.
What is MEDCAP AB SK-40's market cap?
MEDCAP AB SK-40's market capitalization is EUR 695.02M.
What is MEDCAP AB SK-40's P/E ratio?
MEDCAP AB SK-40's price-to-earnings (P/E) ratio is 34.1.
What does MEDCAP AB SK-40 do?
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals;